Generation of the human pluripotent stem cell lines KUMi005-A from a patients with multiple myeloma

Ji-Hea Kim; Ji-Hyeon Hong; Ka-Won Kang; Byung-Hyun Lee; Young Park; Byung-Soo Kim

doi:10.1016/j.scr.2022.102939

Generation of the human pluripotent stem cell lines KUMi005-A from a patients with multiple myeloma

Stem Cell Res. 2022 Dec:65:102939. doi: 10.1016/j.scr.2022.102939. Epub 2022 Oct 13.

Authors

Ji-Hea Kim¹, Ji-Hyeon Hong², Ka-Won Kang³, Byung-Hyun Lee³, Young Park³, Byung-Soo Kim⁴

Affiliations

¹ Institute of Stem Cell Research, Korea University College of Medicine, Seoul, South Korea; Department of Biomedical and Science, Graduate School of Medicine, Korea University, Seoul, South Korea.
² Institute of Stem Cell Research, Korea University College of Medicine, Seoul, South Korea.
³ Department of Internal Medicine, Korea University Medical School Hospital, Seoul, South Korea.
⁴ Institute of Stem Cell Research, Korea University College of Medicine, Seoul, South Korea; Department of Biomedical and Science, Graduate School of Medicine, Korea University, Seoul, South Korea; Department of Internal Medicine, Korea University Medical School Hospital, Seoul, South Korea.

PMID: 36332466
DOI: 10.1016/j.scr.2022.102939

Abstract

Multiple myeloma (MM) progresses with abnormal monoclonal proliferation and accumulation of malignant plasma cells in the bone marrow. We established human induced pluripotent stem cells (iPSCs), KUMi005-A, from bone marrow samples of a patient with MM. This reprogrammed cell line has similar characteristics to human embryonic stem cells, such as proliferation properties and pluripotency. KUMi005-A iPSCs may be applicable in MM disease modeling and cell-based therapies.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Cell Line
Humans
Induced Pluripotent Stem Cells*
Multiple Myeloma*